Literature DB >> 12717436

Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Marco Tartaglia1, Charlotte M Niemeyer, Alessandra Fragale, Xiaoling Song, Jochen Buechner, Andreas Jung, Karel Hählen, Henrik Hasle, Jonathan D Licht, Bruce D Gelb.   

Abstract

We report here that individuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations in PTPN11 and that somatic mutations in PTPN11 account for 34% of non-syndromic JMML. Furthermore, we found mutations in PTPN11 in a small percentage of individuals with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML). Functional analyses documented that the two most common mutations in PTPN11 associated with JMML caused a gain of function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12717436     DOI: 10.1038/ng1156

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  310 in total

1.  Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Camille B Troup; Laura C Gelston; John Haliburton; Eric D Chow; Kristie B Yu; Jon Akutagawa; Amaro N Taylor-Weiner; Y Lucy Liu; Yong-Dong Wang; Kyle Beckman; Peter D Emanuel; Benjamin S Braun; Adam Abate; Robert B Gerbing; Todd A Alonzo; Mignon L Loh
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

2.  Third International Symposium on Myelodysplastic Syndromes in Childhood.

Authors:  Atsushi Manabe; Yoshitoshi Ohtsuka
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

3.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 4.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

5.  Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.

Authors:  Hong Zheng; Wen-Mei Yu; Ronald R Waclaw; Maria I Kontaridis; Benjamin G Neel; Cheng-Kui Qu
Journal:  Sci Signal       Date:  2018-03-20       Impact factor: 8.192

6.  DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia.

Authors:  W S Stevenson; O G Best; A Przybylla; Q Chen; N Singh; M Koleth; S Pierce; T Kennedy; W Tong; S-Q Kuang; G Garcia-Manero
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

7.  Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.

Authors:  Jie Xu; Li-Fan Zeng; Weihua Shen; John J Turchi; Zhong-Yin Zhang
Journal:  Biochem Biophys Res Commun       Date:  2013-09-13       Impact factor: 3.575

8.  Correlation Between Expression of the Cancer/Testis Antigen KK-LC-1 and Helicobacter pylori Infection in Gastric Cancer.

Authors:  Takashi Fukuyama; Nobue Futawatari; Yoshinobu Ichiki; Akiko Shida; Taiga Yamazaki; Yatsushi Nishi; Hiroshi Nonoguchi; Yoshihito Takahashi; Hitoshi Yamazaki; Noritada Kobayashi
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

9.  Biochemical and functional characterization of germ line KRAS mutations.

Authors:  Suzanne Schubbert; Gideon Bollag; Natalya Lyubynska; Hoa Nguyen; Christian P Kratz; Martin Zenker; Charlotte M Niemeyer; Anders Molven; Kevin Shannon
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

10.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.